2011
First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma.
Sosman J, Adjei A, LoRusso P, Michael S, Dy G, Bowditch A, Chmielowski B, Lee S, Walker R, Faucette S, Izmailova E, Bozon V, Ribas A. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma. Journal Of Clinical Oncology 2011, 29: tps145-tps145. DOI: 10.1200/jco.2011.29.15_suppl.tps145.Peer-Reviewed Original Research
2005
Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients
Menon S, Whitfield L, Sadis S, Meyer M, Leopold J, Lorusso P, Krishnamurthi S, Rinehart J, Nabell L, Croghan G. Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients. Journal Of Clinical Oncology 2005, 23: 3066-3066. DOI: 10.1200/jco.2005.23.16_suppl.3066.Peer-Reviewed Original ResearchA phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer
Lorusso P, Krishnamurthi S, Rinehart J, Nabell L, Croghan G, Varterasian M, Sadis S, Menon S, Leopold J, Meyer M. A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. Journal Of Clinical Oncology 2005, 23: 3011-3011. DOI: 10.1200/jco.2005.23.16_suppl.3011.Peer-Reviewed Original Research